Klamroth R - Search Results

1

[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].

Dempfle CE, Gulba D, Kirchmaier CM, Klamroth R, Korte W, Lorenz R, Peck-Radosavljevic M, Veldman A, Zotz RB. Dempfle CE, et al. Among authors: klamroth r. Med Klin (Munich). 2007 Jan 15;102(1):70-81. doi: 10.1007/s00063-007-1012-9. Med Klin (Munich). 2007. PMID: 17221356 German.

2

[Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].

Auerswald G, Muntean W, Kemkes-Matthes B, Klamroth R, Krause M, Kurnik K, Oldenburg J, Pabinger-Fasching I, Schramm W, Zimmermann R, Zotz RB. Auerswald G, et al. Among authors: klamroth r. Hamostaseologie. 2009 May;29(2):197-203. Hamostaseologie. 2009. PMID: 19404511 German.

3

Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.

Birschmann I, Klamroth R, Eichler H, Schenk J, Kirchmaier CM, Halimeh S. Birschmann I, et al. Among authors: klamroth r. Haemophilia. 2013 Sep;19(5):679-85. doi: 10.1111/hae.12156. Epub 2013 May 7. Haemophilia. 2013. PMID: 23647644

4

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.

Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A. Oldenburg J, et al. Among authors: klamroth r. Hamostaseologie. 2021 Jun;41(3):184-189. doi: 10.1055/a-1469-7481. Epub 2021 Apr 1. Hamostaseologie. 2021. PMID: 33822348

5

Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.

Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A. Oldenburg J, et al. Among authors: klamroth r. Hamostaseologie. 2021 Jun;41(3):e1. doi: 10.1055/s-0041-1729135. Epub 2021 May 12. Hamostaseologie. 2021. PMID: 33979842 Free article. No abstract available.

6

[Haemophilia A and haemophilia B. Are there relevant clinical differences?].

Klamroth R, Orlovic M, Kubicek-Hofman C, Gottstein S. Klamroth R, et al. Hamostaseologie. 2010 Nov;30 Suppl 1:S26-7. Hamostaseologie. 2010. PMID: 21042678 German.

7

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I; AFFINITY Investigators. Mahlangu J, et al. Among authors: klamroth r. Blood. 2016 Aug 4;128(5):630-7. doi: 10.1182/blood-2016-01-687434. Epub 2016 Jun 21. Blood. 2016. PMID: 27330001 Free PMC article. Clinical Trial.

8

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.

Klamroth R, Simpson M, von Depka-Prondzinski M, Gill JC, Morfini M, Powell JS, Santagostino E, Davis J, Huth-Kühne A, Leissinger C, Neumeister P, Bensen-Kennedy D, Feussner A, Limsakun T, Zhou M, Veldman A, St Ledger K, Blackman N, Pabinger I. Klamroth R, et al. Haemophilia. 2016 Sep;22(5):730-8. doi: 10.1111/hae.12985. Epub 2016 Jul 19. Haemophilia. 2016. PMID: 27434619 Clinical Trial.

9

[Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].

Siegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R. Siegmund B, et al. Among authors: klamroth r. Hamostaseologie. 2010 Nov;30 Suppl 1:S37-9. Hamostaseologie. 2010. PMID: 21042673 German.

10

Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.

Pollmann H, Klamroth R, Vidovic N, Kriukov AY, Epstein J, Abraham I, Spotts G, Oldenburg J. Pollmann H, et al. Among authors: klamroth r. Ann Hematol. 2013 May;92(5):689-98. doi: 10.1007/s00277-013-1678-4. Epub 2013 Jan 17. Ann Hematol. 2013. PMID: 23324986

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page